Louisville, KY · Opioid MAT

Medication-Assisted Treatment for opioid use disorder

MAT is the clinical standard of care for opioid use disorder. Suboxone, methadone, Vivitrol, and naltrexone are all typically covered by Kentucky Medicaid plans and reduce overdose mortality by more than half when continued long-term.

Kentucky Medicaid plans typically cover MAT

Kentucky Medicaid plans typically cover Suboxone, Subutex, methadone, Vivitrol, and oral naltrexone for opioid use disorder. Pick your plan to see specific formulations, authorization, and pharmacy benefit details.

Medications we offer

Buprenorphine + naloxone

Suboxone

Office-based daily sublingual dosing. Partial agonist with built-in misuse deterrent.

Suboxone treatment →
Buprenorphine alone

Subutex

Used during pregnancy when the naloxone in Suboxone isn't appropriate.

Full opioid agonist

Methadone

Daily on-site dosing at a federally licensed Opioid Treatment Program (OTP).

Extended-release naltrexone

Vivitrol

Monthly injection. Requires 7-14 days opioid-free before the first dose.

Daily oral antagonist

Oral naltrexone

Pill form of the same medication as Vivitrol. Lower adherence than injection.

Verify your MAT coverage and start treatment

Call us or send a message — we'll discuss your situation and help you understand your treatment options.

Frequently asked questions

Will my Kentucky Medicaid plan cover MAT?

Yes. Kentucky Medicaid plans typically cover MAT for opioid use disorder. Pharmacy prior authorization may apply to specific formulations.

Which MAT is right for me?

It depends on overdose risk, prior treatment history, pregnancy status, ability to attend daily dosing (for methadone), and personal preference. A Golden Grove clinician will help you choose during the assessment.

Can I do MAT during pregnancy?

Yes. Subutex (buprenorphine alone, without naloxone) is the standard MAT for pregnant members with OUD, and is typically covered by Kentucky Medicaid plans. Methadone in an OTP is also a coverage option.

How long should I stay on MAT?

MAT is meant to be a long-term treatment for many patients. There is no clinical evidence that shorter MAT duration improves outcomes. Tapering, when appropriate, should be gradual and clinically guided.